The authors sought to outline ALK mutations linked to resistance to lorlatinib treatment by implementing N-ethyl-N-nitrosourea (ENU) mutagenesis screening [78] of Ba/F3 models of ALK-positive cancer. This evidence concerns the gene ALK and cancer.